Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joshua Epstein

Showing results (41-50 of 85) with videos related to

Pageof 9
Sort By:
American Journal of Hematology|March 5, 2013
Role of Bruton's tyrosine kinase in myeloma cell migration and induction of bone diseaseRakesh Bam, Wen Ling, Sharmin Khan, et al.
Blood|December 3, 2005
Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction and posttransplantation consolidation therapiesBart Barlogie, Guido Tricot, Erik Rasmussen, et al.
Blood|October 9, 2004
Heparanase promotes the spontaneous metastasis of myeloma cells to boneYang Yang, Veronica Macleod, Manali Bendre, et al.
Immunotherapy|February 19, 2016
Monoclonal antibody therapy in multiple myeloma: where do we stand and where are we going?Sharmilan Thanendrarajan, Faith E Davies, Gareth J Morgan, et al.
British Journal of Haematology|December 13, 2006
Complete response in myeloma extends survival without, but not with history of prior monoclonal gammopathy of undetermined significance or smouldering diseaseMauricio Pineda-Roman, Vanessa Bolejack, Varant Arzoumanian, et al.
Blood|April 13, 2012
Prediction of cytogenetic abnormalities with gene expression profilesYiming Zhou, Qing Zhang, Owen Stephens, et al.
Blood|May 16, 2009
F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myelomaTwyla B Bartel, Jeff Haessler, Tracy L Y Brown, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 23, 2018
The Pattern of Mesenchymal Stem Cell Expression Is an Independent Marker of Outcome in Multiple MyelomaCarolina Schinke, Pingping Qu, Syed J Mehdi, et al.
Plos One|September 26, 2013
Characterization of the molecular mechanism of the bone-anabolic activity of carfilzomib in multiple myelomaBo Hu, Yu Chen, Saad Z Usmani, et al.
Blood|April 10, 2007
High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosisFrits van Rhee, Vanessa Bolejack, Klaus Hollmig, et al.
Pageof 9

Showing results (41-50 of 85) with videos related to

Sort By:
Pageof 9
American Journal of Hematology|March 5, 2013
Role of Bruton's tyrosine kinase in myeloma cell migration and induction of bone diseaseRakesh Bam, Wen Ling, Sharmin Khan, et al.
Blood|December 3, 2005
Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction and posttransplantation consolidation therapiesBart Barlogie, Guido Tricot, Erik Rasmussen, et al.
Blood|October 9, 2004
Heparanase promotes the spontaneous metastasis of myeloma cells to boneYang Yang, Veronica Macleod, Manali Bendre, et al.
Immunotherapy|February 19, 2016
Monoclonal antibody therapy in multiple myeloma: where do we stand and where are we going?Sharmilan Thanendrarajan, Faith E Davies, Gareth J Morgan, et al.
British Journal of Haematology|December 13, 2006
Complete response in myeloma extends survival without, but not with history of prior monoclonal gammopathy of undetermined significance or smouldering diseaseMauricio Pineda-Roman, Vanessa Bolejack, Varant Arzoumanian, et al.
Blood|April 13, 2012
Prediction of cytogenetic abnormalities with gene expression profilesYiming Zhou, Qing Zhang, Owen Stephens, et al.
Blood|May 16, 2009
F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myelomaTwyla B Bartel, Jeff Haessler, Tracy L Y Brown, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 23, 2018
The Pattern of Mesenchymal Stem Cell Expression Is an Independent Marker of Outcome in Multiple MyelomaCarolina Schinke, Pingping Qu, Syed J Mehdi, et al.
Plos One|September 26, 2013
Characterization of the molecular mechanism of the bone-anabolic activity of carfilzomib in multiple myelomaBo Hu, Yu Chen, Saad Z Usmani, et al.
Blood|April 10, 2007
High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosisFrits van Rhee, Vanessa Bolejack, Klaus Hollmig, et al.
Pageof 9